Lifestyle Change for Better Health
Reason given: Due to challenges with recruitment, we were unable to complete recruitment as planned during the period we had funding to do so.
Key facts
- Where
- Pittsburgh, United StatesSee the site
Where in United States
- UPMC ShadysidePittsburgh, United StatesNo longer taking part
Trial details
- Who runs it
- University of Pittsburgh
- Trial code
- NCT03286699
- Record updated
- 10 January 2025
- Original description
The goal of the research is to provide a first critical test of the novel scientific idea that a combined diet and exercise intervention may ameliorate shortening of leukocyte telomere length (LTL) in individuals with histories of successfully treated non-metastatic bladder cancer (BC) or colorectal adenoma (CRA) compared to a diet only intervention.Read full original descriptionShow less
Leukocyte Telomere Length: Diet and Exercise Trial
The goal of the research is to provide a first critical test of the novel scientific idea that a combined diet and exercise intervention may ameliorate shortening of leukocyte telomere length (LTL) in individuals with histories of successfully treated non-metastatic bladder cancer (BC) or colorectal adenoma (CRA) compared to a diet only intervention.
Inclusion: BMI between 25.0 to <40 kg/m2 (allows for use of assessments such as DXA to be included); History of histologically confirmed bladder cancer (non-metastatic) or colorectal adenoma; Under clinical surveillance with no evidence of disease.
Exclusion: Currently pregnant or breastfeeding, were pregnant in the previous 6 months or breastfeeding in the previous 3 months, or planning pregnancy in the next year; Cancer diagnosis (other than bladder cancer or non-melanoma skin cancer) in the previous 5 years; Current treatment for psychiatric issues (e.g., depression, bipolar disorder) or taking daily or extended release psychotropic medications in the previous 12 months; History of bariatric surgery; Medical condition that could affect body weight (e.g., diabetes mellitus, hyperthyroidism, uncontrolled hypothyroidism, chronic renal insufficiency, chronic liver disease, gastrointestinal disorders including ulcerative colitis); Current congestive heart failure, signs or symptoms indicative of an increased acute risk for a cardiovascular event; History of myocardial infarction, coronary artery bypass or angioplasty, conditions requiring chronic anticoagulation (recent or recurrent DVT); Eating disorder that would contraindicate weight loss or physical activity; WHO performance status 3-4 or deemed physically unable to participate by physician; Resting systolic blood pressure of >160 mmHg or diastolic blood pressure >100 mmHg; Alcohol or substance abuse; Report exercising more than 100 minutes per week over the past 3 months (NOTE: includes physical activity performed for sport, fitness, or recreational activity; physical activity performed as part of occupation or household chores is not included); Weight loss of greater than 5% or participating in a weight reduction diet in the past 3 months; Report plans to relocate to a location not accessible to the study site or having employment, personal, or travel commitments that prohibit attendance to at least 80 percent of the scheduled intervention sessions and all of the scheduled assessments.